Cargando…
Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease
Neuropathic Gaucher disease (nGD), also known as type 2 or type 3 Gaucher disease, is caused by a deficiency of the enzyme glucocerebrosidase (GC). This deficiency impairs the degradation of glucosylceramide (GluCer) and glucosylsphingosine (GluSph), leading to their accumulation in the brains of pa...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422338/ https://www.ncbi.nlm.nih.gov/pubmed/22912851 http://dx.doi.org/10.1371/journal.pone.0043310 |
_version_ | 1782241038973272064 |
---|---|
author | Cabrera-Salazar, Mario A. DeRiso, Matthew Bercury, Scott D. Li, Lingyun Lydon, John T. Weber, William Pande, Nilesh Cromwell, Mandy A. Copeland, Diane Leonard, John Cheng, Seng H. Scheule, Ronald K. |
author_facet | Cabrera-Salazar, Mario A. DeRiso, Matthew Bercury, Scott D. Li, Lingyun Lydon, John T. Weber, William Pande, Nilesh Cromwell, Mandy A. Copeland, Diane Leonard, John Cheng, Seng H. Scheule, Ronald K. |
author_sort | Cabrera-Salazar, Mario A. |
collection | PubMed |
description | Neuropathic Gaucher disease (nGD), also known as type 2 or type 3 Gaucher disease, is caused by a deficiency of the enzyme glucocerebrosidase (GC). This deficiency impairs the degradation of glucosylceramide (GluCer) and glucosylsphingosine (GluSph), leading to their accumulation in the brains of patients and mouse models of the disease. These accumulated substrates have been thought to cause the severe neuropathology and early death observed in patients with nGD and mouse models. Substrate accumulation is evident at birth in both nGD mouse models and humans affected with the most severe type of the disease. Current treatment of non-nGD relies on the intravenous delivery of recombinant human glucocerebrosidase to replace the missing enzyme or the administration of glucosylceramide synthase inhibitors to attenuate GluCer production. However, the currently approved drugs that use these mechanisms do not cross the blood brain barrier, and thus are not expected to provide a benefit for the neurological complications in nGD patients. Here we report the successful reduction of substrate accumulation and CNS pathology together with a significant increase in lifespan after systemic administration of a novel glucosylceramide synthase inhibitor to a mouse model of nGD. To our knowledge this is the first compound shown to cross the blood brain barrier and reduce substrates in this animal model while significantly enhancing its lifespan. These results reinforce the concept that systemically administered glucosylceramide synthase inhibitors could hold enhanced therapeutic promise for patients afflicted with neuropathic lysosomal storage diseases. |
format | Online Article Text |
id | pubmed-3422338 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-34223382012-08-21 Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease Cabrera-Salazar, Mario A. DeRiso, Matthew Bercury, Scott D. Li, Lingyun Lydon, John T. Weber, William Pande, Nilesh Cromwell, Mandy A. Copeland, Diane Leonard, John Cheng, Seng H. Scheule, Ronald K. PLoS One Research Article Neuropathic Gaucher disease (nGD), also known as type 2 or type 3 Gaucher disease, is caused by a deficiency of the enzyme glucocerebrosidase (GC). This deficiency impairs the degradation of glucosylceramide (GluCer) and glucosylsphingosine (GluSph), leading to their accumulation in the brains of patients and mouse models of the disease. These accumulated substrates have been thought to cause the severe neuropathology and early death observed in patients with nGD and mouse models. Substrate accumulation is evident at birth in both nGD mouse models and humans affected with the most severe type of the disease. Current treatment of non-nGD relies on the intravenous delivery of recombinant human glucocerebrosidase to replace the missing enzyme or the administration of glucosylceramide synthase inhibitors to attenuate GluCer production. However, the currently approved drugs that use these mechanisms do not cross the blood brain barrier, and thus are not expected to provide a benefit for the neurological complications in nGD patients. Here we report the successful reduction of substrate accumulation and CNS pathology together with a significant increase in lifespan after systemic administration of a novel glucosylceramide synthase inhibitor to a mouse model of nGD. To our knowledge this is the first compound shown to cross the blood brain barrier and reduce substrates in this animal model while significantly enhancing its lifespan. These results reinforce the concept that systemically administered glucosylceramide synthase inhibitors could hold enhanced therapeutic promise for patients afflicted with neuropathic lysosomal storage diseases. Public Library of Science 2012-08-17 /pmc/articles/PMC3422338/ /pubmed/22912851 http://dx.doi.org/10.1371/journal.pone.0043310 Text en © 2012 Cabrera-Salazar et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Cabrera-Salazar, Mario A. DeRiso, Matthew Bercury, Scott D. Li, Lingyun Lydon, John T. Weber, William Pande, Nilesh Cromwell, Mandy A. Copeland, Diane Leonard, John Cheng, Seng H. Scheule, Ronald K. Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease |
title | Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease |
title_full | Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease |
title_fullStr | Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease |
title_full_unstemmed | Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease |
title_short | Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease |
title_sort | systemic delivery of a glucosylceramide synthase inhibitor reduces cns substrates and increases lifespan in a mouse model of type 2 gaucher disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422338/ https://www.ncbi.nlm.nih.gov/pubmed/22912851 http://dx.doi.org/10.1371/journal.pone.0043310 |
work_keys_str_mv | AT cabrerasalazarmarioa systemicdeliveryofaglucosylceramidesynthaseinhibitorreducescnssubstratesandincreaseslifespaninamousemodeloftype2gaucherdisease AT derisomatthew systemicdeliveryofaglucosylceramidesynthaseinhibitorreducescnssubstratesandincreaseslifespaninamousemodeloftype2gaucherdisease AT bercuryscottd systemicdeliveryofaglucosylceramidesynthaseinhibitorreducescnssubstratesandincreaseslifespaninamousemodeloftype2gaucherdisease AT lilingyun systemicdeliveryofaglucosylceramidesynthaseinhibitorreducescnssubstratesandincreaseslifespaninamousemodeloftype2gaucherdisease AT lydonjohnt systemicdeliveryofaglucosylceramidesynthaseinhibitorreducescnssubstratesandincreaseslifespaninamousemodeloftype2gaucherdisease AT weberwilliam systemicdeliveryofaglucosylceramidesynthaseinhibitorreducescnssubstratesandincreaseslifespaninamousemodeloftype2gaucherdisease AT pandenilesh systemicdeliveryofaglucosylceramidesynthaseinhibitorreducescnssubstratesandincreaseslifespaninamousemodeloftype2gaucherdisease AT cromwellmandya systemicdeliveryofaglucosylceramidesynthaseinhibitorreducescnssubstratesandincreaseslifespaninamousemodeloftype2gaucherdisease AT copelanddiane systemicdeliveryofaglucosylceramidesynthaseinhibitorreducescnssubstratesandincreaseslifespaninamousemodeloftype2gaucherdisease AT leonardjohn systemicdeliveryofaglucosylceramidesynthaseinhibitorreducescnssubstratesandincreaseslifespaninamousemodeloftype2gaucherdisease AT chengsengh systemicdeliveryofaglucosylceramidesynthaseinhibitorreducescnssubstratesandincreaseslifespaninamousemodeloftype2gaucherdisease AT scheuleronaldk systemicdeliveryofaglucosylceramidesynthaseinhibitorreducescnssubstratesandincreaseslifespaninamousemodeloftype2gaucherdisease |